Geode Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-593,430
| Closed | -$60.5M | – | 4814 |
|
|
2023
Q2 | $60.5M | Buy |
593,430
+44,117
| +8% | +$4.17M | 0.01% | 1110 |
|
|
2023
Q1 | $49.9M | Buy |
549,313
+23,197
| +4% | +$1.36M | 0.01% | 1187 |
|
|
2022
Q4 | $20M | Buy |
526,116
+22,196
| +4% | +$764K | ﹤0.01% | 1775 |
|
|
2022
Q3 | $12.7M | Buy |
503,920
+12,055
| +2% | +$334K | ﹤0.01% | 2070 |
|
|
2022
Q2 | $14.9M | Buy |
491,865
+40,943
| +9% | +$1.22M | ﹤0.01% | 1972 |
|
|
2022
Q1 | $14.8M | Sell |
450,922
-11,659
| -3% | -$346K | ﹤0.01% | 2086 |
|
|
2021
Q4 | $12.2M | Sell |
462,581
-15,251
| -3% | -$1.18M | ﹤0.01% | 2315 |
|
|
2021
Q3 | $48.1M | Buy |
477,832
+1,389
| +0.3% | +$163K | 0.01% | 1313 |
|
|
2021
Q2 | $67.4M | Buy |
476,443
+140,402
| +42% | +$15.9M | 0.01% | 1058 |
|
|
2021
Q1 | $33.5M | Buy |
336,041
+20,319
| +6% | +$2.37M | 0.01% | 1523 |
|
|
2020
Q4 | $39M | Buy |
315,722
+34,400
| +12% | +$4.52M | 0.01% | 1285 |
|
|
2020
Q3 | $27.4M | Sell |
281,322
-26,985
| -9% | -$3.37M | 0.01% | 1293 |
|
|
2020
Q2 | $48.1M | Sell |
308,307
-58,377
| -16% | -$8.87M | 0.01% | 915 |
|
|
2020
Q1 | $52.9M | Buy |
366,684
+27,562
| +8% | +$5.32M | 0.01% | 747 |
|
|
2019
Q4 | $69.3M | Buy |
339,122
+45,169
| +15% | +$8.24M | 0.01% | 762 |
|
|
2019
Q3 | $23.6M | Buy |
293,953
+52,904
| +22% | +$4.49M | 0.01% | 1370 |
|
|
2019
Q2 | $22.7M | Buy |
241,049
+25,043
| +12% | +$2.16M | 0.01% | 1402 |
|
|
2019
Q1 | $18.5M | Buy |
216,006
+23,700
| +12% | +$1.97M | ﹤0.01% | 1463 |
|
|
2018
Q4 | $10.8M | Buy |
192,306
+10,958
| +6% | +$669K | ﹤0.01% | 1738 |
|
|
2018
Q3 | $14.8M | Buy |
181,348
+39,926
| +28% | +$2.81M | ﹤0.01% | 1631 |
|
|
2018
Q2 | $4.95M | Buy |
141,422
+27,191
| +24% | +$828K | ﹤0.01% | 2332 |
|
|
2018
Q1 | $2.34M | Buy |
114,231
+83
| +0.1% | +$2.14K | ﹤0.01% | 2675 |
|
|
2017
Q4 | $3.23M | Buy |
114,148
+18,142
| +19% | +$506K | ﹤0.01% | 2476 |
|
|
2017
Q3 | $2.98M | Buy |
96,006
+27,686
| +41% | +$833K | ﹤0.01% | 2512 |
|
|
2017
Q2 | $2.16M | Buy |
68,320
+4,542
| +7% | +$112K | ﹤0.01% | 2689 |
|
|
2017
Q1 | $1.44M | Buy |
63,778
+10,397
| +19% | +$257K | ﹤0.01% | 2833 |
|
|
2016
Q4 | $1.17M | Buy |
53,381
+758
| +1% | +$19.2K | ﹤0.01% | 2916 |
|
|
2016
Q3 | $1.39M | Buy |
+52,623
| New | +$1.04M | ﹤0.01% | 2765 |
|
Other funds holding RETA
Geode Capital Management's RETA Position: Q3 2023 in Review
Geode Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 593,430 shares — an estimated $60.5M sold.
Geode Capital Management first reported a position in RETA in Q3 2016 and held it in 28 quarters. The position peaked at $69.3M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Geode Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Geode Capital Management sold 593,430 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $60.5M.
- Geode Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2016 and held it in 28 quarters.
- Geode Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $69.3M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Geode Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.